1600016N20Rik Inhibitors
Chemical inhibitors of the protein encoded by the gene 1600016N20Rik can be effective in modulating its activity through various points of intervention within the PI3K/Akt signaling pathway. Wortmannin and LY294002 are direct inhibitors of phosphoinositide 3-kinases (PI3K), which are upstream initiators of the pathway. Their inhibition results in decreased phosphorylation of Akt, a kinase that is central to the signaling cascade. As a consequence, the protein encoded by 1600016N20Rik, which is a downstream target of this pathway, experiences reduced activity due to the lack of necessary phosphorylation signals. Similarly, MK-2206 directly inhibits Akt, thereby preventing the activation of not only Akt itself but also its downstream targets, including the 1600016N20Rik protein. Rapamycin, on the other hand, specifically targets and inhibits mTOR, a key downstream effector in the PI3K/Akt pathway. Inhibition by Rapamycin, therefore, suppresses the downstream signaling that would normally include the activation of the 1600016N20Rik protein.
Further upstream, Dasatinib broadly targets tyrosine kinases that may influence the PI3K/Akt pathway and, by extension, the activity of the 1600016N20Rik protein. Meanwhile, inhibitors such as SB203580 and SP600125 interfere with the MAP kinase pathways (p38 MAP kinase and JNK, respectively), which can intersect with the PI3K/Akt pathway and modulate the activity of the protein encoded by 1600016N20Rik through complex signaling cross-talk. Furthermore, PD98059 and U0126, which are selective inhibitors of MEK1/2, act to reduce the activation of the ERK pathway. The ERK pathway is another route that can influence the PI3K/Akt pathway, and its inhibition can have repercussions on the functional status of the 1600016N20Rik protein. Lastly, Bisindolylmaleimide I and Staurosporine inhibit protein kinase C (PKC) and a broad spectrum of protein kinases, respectively. These diverse sets of kinases can modulate the PI3K/Akt pathway at various junctures, leading to a reduction in the activity of the 1600016N20Rik protein by limiting the phosphorylation and activation signals that are critical for its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Given that 1600016N20Rik is a part of the PI3K/Akt signaling pathway, inhibition of PI3K by Wortmannin would lead to a reduction in Akt activation, which in turn inhibits the phosphorylation and activity of downstream targets including 1600016N20Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that directly binds to the ATP binding site of the enzyme. By inhibiting PI3K, LY294002 prevents the phosphorylation and activation of Akt, which is upstream of 1600016N20Rik. This results in a functional inhibition of 1600016N20Rik by disrupting the signaling cascade necessary for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a downstream component of the PI3K/Akt pathway. Since the activity of 1600016N20Rik is dependent on signals propagated through this pathway, Rapamycin-induced mTOR inhibition would suppress the function of 1600016N20Rik by disrupting the pathway's downstream signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. The p38 MAP kinase pathway can intersect with the PI3K/Akt pathway, which is involved in the regulation of 1600016N20Rik. Inhibition of p38 MAP kinase by SB203580 can therefore indirectly inhibit the function of 1600016N20Rik through attenuated cross-talk between these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, which are upstream activators of the ERK pathway. Inhibition of MEK by PD98059 would lead to reduced ERK pathway activity, potentially decreasing the regulatory influence it has on the PI3K/Akt pathway and indirectly inhibiting 1600016N20Rik activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of ERK1/2. By inhibiting MEK, U0126 can indirectly lead to the functional inhibition of 1600016N20Rik by reducing ERK-mediated signaling events that may affect the PI3K/Akt pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling family. JNK can have regulatory effects on the PI3K/Akt pathway, and thus, inhibition of JNK by SP600125 could lead to a decrease in 1600016N20Rik activity by diminishing signaling through the PI3K/Akt pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that might inhibit kinases which interact with the PI3K/Akt pathway. By inhibiting these kinases, Dasatinib can indirectly decrease the functional activity of 1600016N20Rik through reduced phosphorylation and activation within this pathway. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206 is an allosteric inhibitor of AKT, which plays a central role in the PI3K/Akt pathway. Inhibition of AKT by MK-2206 would directly diminish the phosphorylation and activation of downstream targets such as 1600016N20Rik, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of protein kinase C (PKC), which can modulate the PI3K/Akt pathway. Inhibition of PKC by Bisindolylmaleimide I could indirectly inhibit 1600016N20Rik by diminishing the activity of the PI3K/Akt pathway. | ||||||